Bisphosphonates May Raise Uveitis Risk in Osteoporosis Patients

Researchers examined anonymous health records from a big US database called TriNetX. They looked at people who had at least two bone‑loss diagnoses between 2013 and 2024. These patients were split into those who took bisphosphonate pills and those who did not. The study covered more than a decade of data and included thousands of patients.

Taking the medication raised the chance of eye inflammation, especially in the first weeks after starting. The risk was about two times higher for overall uveitis (HR 2.22) and even more for the front part of the eye (HR 2.57). Even though the numbers got smaller later, the link stayed clear all through the study. The analysis used matched groups to make sure the comparison was fair.

People who already had autoimmune diseases faced an even bigger jump in risk. Their hazard ratios were around 2.2 for overall uveitis, 2.2 for the front eye, and 2.5 for the back eye. This shows the drug may be riskier for those with existing immune problems. The higher risk persisted for the whole follow‑up period, not just the early months.

Because many doctors prescribe bisphosphonates for osteoporosis, they should watch for eye symptoms early. Spotting uveitis quickly can lead to faster treatment and better outcomes for patients. Doctors can use this information to include eye checks in regular follow‑up visits.